查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1532644

肝癌藥物市場規模- 按類型（HCC、膽管癌、肝母細胞瘤）、藥物類別（化療​​、標靶和免疫治療）、給藥途徑（口服、注射）、藥物類型（品牌、學名藥）、性別與預測，2024 - 2032

Liver Cancer Drugs Market Size - By Type (HCC, Cholangiocarcinoma, Hepatoblastoma), Drug Class (Chemotherapeutics, Targeted & Immunotherapy), Route of Administration (Oral, Injectable), Medication Type (Branded, Generics), Gender & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

據世界衛生組織稱，由於全球肝癌盛行率不斷上升，過去二十年肝癌發病率增加了 75%，預計 2024 年至 2032 年肝癌藥物市場的複合年成長率將達到 11.8%。 CDC 的報告稱，這一成長主要歸因於人口老化、飲酒量增加以及乙型肝炎和丙型肝炎的廣泛發病，這些疾病影響全球超過 3.25 億人。此外，生活方式因素，特別是肥胖和糖尿病，進一步增加了肝癌的發生率。因此，對更有效治療方法的需求日益成長，從而刺激了先進肝癌藥物的創新和商業化。

標靶療法和免疫療法的出現正在重塑肝癌治療格局。例如，根據美國國家癌症研究所的數據，索拉非尼和納武單抗等藥物在臨床試驗中顯示出顯著的療效。此外，在政府支持的支持下，製藥實體增加了研發投資，正在加快藥物發現和批准時間。這些進步不僅拓寬了治療範圍，也提高了肝癌藥物的安全性和有效性基準，進一步推動市場擴張。

全球肝癌藥物產業根據類型、藥物類別、給藥途徑、藥物類型、性別和地區進行分類。

由於發病率不斷上升，特別是在兒科患者中，肝母細胞瘤類型預計到 2032 年將顯著成長。肝母細胞瘤是兒童最常見的肝癌，需要與成人肝癌不同的專門治療方案。隨著對肝母細胞瘤的認知和早期診斷的提高，針對該患者群體的針對性和有效治療的需求不斷成長。製藥公司越來越注重開發專門針對肝母細胞瘤的創新藥物和治療方案。再加上旨在了解和對抗肝母細胞瘤的研究工作和臨床試驗的加強，將有利於該細分市場的佔有率。

由於便利性和有效性，口腔肝癌藥物產業領域將在預測期內獲得巨大的吸引力。口服藥物提供了靜脈注射治療的非侵入性替代方案，允許患者在家中服用，從而提高依從性並降低醫療成本。製藥技術的進步已經生產出了高效的口服藥物，具有更好的生物利用度和針對性的作用，最大限度地減少副作用並改善治療結果。此外，口服製劑的便利性，加上支持其功效和安全性的強力的臨床證據，使它們成為患者和醫療保健提供者的首選。

到2032年，亞太地區肝癌藥物市場將呈現強勁成長趨勢，這得益於肝癌的高盛行率，特別是由於廣泛的乙型和丙型肝炎感染以及飲酒和肥胖率上升。此外，中國和印度等國家不斷增加的醫療保健支出和改善醫療基礎設施正在促進更好地獲得先進治療。旨在加強癌症護理和研究的政府措施和支持政策也有助於市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 肝癌負擔不斷增加
      • 增加新療法開發的研發投資
      • 人口老化加劇
      • 政府提高癌症意識的舉措
    • 產業陷阱與挑戰
      • 與某些藥物相關的副作用
      • 癌症治療費用高
  • 成長潛力分析
  • 管道分析
  • 監管環境
  • 未來市場趨勢
  • 波特分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

  • 主要趨勢
  • 肝細胞癌
  • 膽管癌
  • 肝母細胞瘤
  • 肝轉移
  • 其他類型

第 6 章：市場估計與預測：按藥物類別，2021 - 2032 年

  • 主要趨勢
  • 化療藥物
  • 標靶治療藥物
  • 免疫治療藥物

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

  • 主要趨勢
  • 口服
  • 可注射

第 8 章：市場估計與預測：按藥物類型，2021 - 2032

  • 主要趨勢
  • 通用的
  • 品牌化

第 9 章：市場估計與預測：按性別分類，2021 - 2032 年

  • 主要趨勢
  • 男性
  • 女性

第 10 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 11 章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
簡介目錄
Product Code: 9707

The liver cancer drugs market is estimated to register 11.8% CAGR during 2024 and 2032, driven by the escalating global prevalence of liver cancer, which has seen a 75% increase in incidence over the past two decades, according to WHO. This rise is primarily attributed to an aging population, heightened alcohol consumption, and the widespread incidence of hepatitis B and C, which affect over 325 million people worldwide, cites CDC report. Moreover, lifestyle elements, notably obesity and diabetes, are further bolstering the incidence of liver cancer. Consequently, there's a mounting need for more effective treatments, spurring the innovation and commercialization of advanced liver cancer drugs.

The advent of targeted and immunotherapies is reshaping liver cancer treatment landscape. For instance, as per National Cancer Institute, drugs like Sorafenib and Nivolumab have shown significant efficacy in clinical trials. Moreover, amplified R&D investments from pharmaceutical entities, bolstered by government backing, are expediting drug discovery and approval timelines. These strides not only broaden the treatment spectrum but also elevate the safety and efficacy benchmarks of liver cancer drugs, further propelling market expansion.

The global liver cancer drugs industry is classified based on type, drug class, route of administration, medication type, gender, and region.

The hepatoblastoma type segment is poised to significantly growth through 2032, due to increasing incidence, particularly among pediatric patients. Hepatoblastoma, the most common liver cancer in children, necessitates specialized treatment options that differ from those used for adult liver cancers. As awareness and early diagnosis of hepatoblastoma improve, there is a growing demand for targeted and effective therapies tailored to this patient population. Pharmaceutical companies are increasingly focusing on developing innovative drugs and treatment protocols specifically for hepatoblastoma. This, along with enhanced research efforts and clinical trials aimed at understanding and combating hepatoblastoma will favor the segment share.

The oral liver cancer drugs industry segment will gain substantial traction over the forecast period, owing to convenience and effectiveness. Oral medications offer a non-invasive alternative to intravenous treatments, allowing patients to take them at home, which improves compliance and reduces healthcare costs. Advances in pharmaceutical technology have produced highly effective oral drugs with better bioavailability and targeted action, minimizing side effects and improving treatment outcomes. Additionally, the convenience of oral formulations, coupled with strong clinical evidence supporting their efficacy and safety, makes them a preferred choice for both patients and healthcare providers.

Asia Pacific liver cancer drugs market will exhibit strong growth trends through 2032, backed by a high prevalence of liver cancer, particularly due to widespread hepatitis B and C infections and rising rates of alcohol consumption and obesity. Additionally, increasing healthcare expenditure and improving medical infrastructure in countries such as China and India are facilitating better access to advanced treatments. Government initiatives and supportive policies aimed at enhancing cancer care and research are also contributing to market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising burden of liver cancer
      • 3.2.1.2 Increasing R&D investments for the development of novel therapies
      • 3.2.1.3 Rising aging population
      • 3.2.1.4 Government initiatives to increase cancer awareness
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Side effects associated with certain medications
      • 3.2.2.2 High cost of cancer therapies
  • 3.3 Growth potential analysis
  • 3.4 Pipeline analysis
  • 3.5 Regulatory landscape
  • 3.6 Future market trends
  • 3.7 Porters analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Hepatocellular carcinoma
  • 5.3 Cholangiocarcinoma
  • 5.4 Hepatoblastoma
  • 5.5 Liver metastasis
  • 5.6 Other types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Chemotherapeutic agents
  • 6.3 Targeted therapy drugs
  • 6.4 Immunotherapy drugs

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Generic
  • 8.3 Branded

Chapter 9 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Male
  • 9.3 Female

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 South Africa
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 AbbVie Inc.
  • 11.2 Amgen Inc.
  • 11.3 AstraZeneca Plc
  • 11.4 Bayer AG
  • 11.5 Bristol-Myers Squibb Company
  • 11.6 Eisai Co., Ltd.
  • 11.7 Exelixis, Inc.
  • 11.8 F. Hoffmann-La Roche Ltd.
  • 11.9 Johnson & Johnson
  • 11.10 Merck & Co., Inc.
  • 11.11 Novartis AG
  • 11.12 Sanofi SA
  • 11.13 Thermo Fisher Scientific Inc.